This Biotech Is Targeting Indications Worth $70 Billion
Benzinga
Benzinga
  • 4 months ago
Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. was recently a guest on Benzinga’s All-Access.

ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop transformative drugs for underserved patients with renal and inflammatory diseases. The company is currently advancing a therapeutic pipeline with multiple programs built around its two proprietary technologies – VAR 200 and IC 100.

The technologies could represent a leap forward in the treatment of several diseases.
Recommended
0:36
I
Up next
Olivier Véran: "S'ils sont les mêmes indications et les mêmes contre-indications, les vaccins seront proposés indistinctement"
BFMTV
2:22
Atarax 25 mg 100 mg Indications, contre indications, effets secondaires
Martha Brock
5:07
Causes Of Brain Diseases | Brain Exercises | causes of brain diseases | brain exercises | brain (anatomical structure),brain diseases,brain,traumatic brain injury (disease or medical condition),symptoms and causes of brain stroke,brain cancer,prime of
Knowldge Factory
0:51
Dangerous diseases | Spread of diseases | Aamer Habib about dangerous diseases
Public TV Media
8:10
Epidemic Diseases Act, 1897 क्या है ? | Epidemic Diseases Act in Hindi | Legal Knowledge | By Expert Vakil Epidemic Diseases Act
Expert Vakil
0:32
Single-Use Technology in Biopharmaceutical Manufacture Review
JaniceSimmons2308
2:58
Types of Diseases _ Infectious Diseases _ Human Health and Diseases _ Disorders
WORLD ENTERTAINMENT
1:58
Samsung breaks ground on 3rd biopharmaceutical factory in S. Korea
Arirang News
0:53
Thousands infected with brucellosis after leak at biopharmaceutical factory in China
Arirang News
Benzinga
0:40
Maryland Teacher Faces Criminal Charges for Spreading an AI-Generated Fake Recording of the Principal Making Racist Comments
Benzinga
0:27
Arizona Grand Jury Indicts 18 Individuals Involved in Submitting Fake Elector Documents
Benzinga
0:46
ByteDance Unlikely to Sell TikTok, Preferring Shutdown in the US to Parting Ways with Its Key Algorithm
Benzinga
0:35
Google Parent Alphabet Announces $70 Billion Stock Buyback Program After Stellar Q1 Results
Benzinga
0:38
Analysts Predict Chevron and ExxonMobil Will Report Lower Q1 Profits Despite Rising Oil Prices
Benzinga
0:39
Meta Stock Plummets 15% as Market Reacts to Increased AI Spending
Benzinga
Featured channels
More from
EarthX
More from
TIME
More from
Insider
More from
What's Trending
More from
Entrepreneur
More from
SportsGrid